Most KN95 masks don’t meet standards To view this email as a web page,
click here Walmart piloting drone delivery for COVID-19 self-swab kits J&J wants everyone to know that taking care of their health can’t wait—even during a pandemic Most KN95 masks fall short of U.S. standards for effectiveness, ECRI finds Biopharma roundup: Serum Institute to crank out Codageix vaccine; Pancreatitis med nafamostat gets COVID-19 test Healthcare roundup: Americans growing skeptical of first wave of COVID vaccines Verma: CMS will mull which COVID-19 flexibilities may stick around post-pandemic Viral vector manufacturer Vibalogics adds CEO to lead expansion, COVID-19 response Featured Story | By Paige Minemyer Walmart is piloting drone delivery of home sample collection kits for COVID-19 in partnership with Quest Diagnostics. read more |
| |
|---|
|
Top Stories By Sharon Klahr Coey Johnson & Johnson Medical Devices recently launched the “My Health Can’t Wait” campaign to give both patients and physicians information and resources about healthcare options during the pandemic. The effort is built around the concern that people are delaying typical medical care. More than two-thirds (68%) of American adults said that they or someone they know has put off care due to the pandemic, according to a recent Harris Poll commissioned by J&J. read more By Tina Reed Up to 70% of KN95 masks manufactured in China do not meet U.S. standards for effectiveness, an analysis by ECRI found. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner The Serum Institute of India will manufacture Codagenix's intranasal vaccine for clinical trials and eventual commercial supply. Russia will cover the legal risks if its vaccine proves unsafe, Reuters reported. Arizona scientists will test nafamostat against COVID-19. And J&J launched a campaign to help patients and docs keep medical care on track. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Paige Minemyer The Trump administration has rolled out a slew of policies aimed at offering greater flexibility to payers and providers amid COVID-19—but what changes are likely to stick around long-term? read more By Kyle Blankenship In the bustling cell and gene therapy space, commercial manufacturing capacity will have a tough time keeping up with the potentially dozens of candidates hitting the market in the coming years, experts say. One German company plans to expand its U.S. footprint to help meet that demand, and it's found the right leader to get it there. read more |
|
